Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
G Ital Dermatol Venereol ; 154(1): 64-71, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29249122

RESUMEN

Despite the presence of several studies in literature, the real connection between vitamin D serological levels, vitamin D receptor and melanoma remains unclear, probably because of the complex correlation between vitamin D and melanoma. Indeed, UV radiations are not reported as the main risk factor for melanoma in non-sun-exposed, while systemic immunosuppression, anatomical and physiological features may contribute to malignancy. Therefore, the correlation between melanoma cells in sun-exposed areas and vitamin D, as well as vitamin D receptor could be different from the one in melanoma of sun-shielded sites. These differences may also explain the controversial results reported in the literature regarding the correlation between melanoma and vitamin D, as well as the different outcomes in melanoma patients treated with vitamin D as adjuvant therapy. The aim of this review is to highlight the most recent findings about vitamin D and melanoma, focusing on the anatomic site of the primary tumor as well as on the possible therapeutic uses of vitamin D in melanoma patients.


Asunto(s)
Melanoma/patología , Neoplasias Cutáneas/patología , Vitamina D/sangre , Animales , Humanos , Melanoma/sangre , Melanoma/terapia , Receptores de Calcitriol/metabolismo , Factores de Riesgo , Neoplasias Cutáneas/sangre , Neoplasias Cutáneas/terapia , Luz Solar/efectos adversos , Vitamina D/administración & dosificación
2.
Int J Immunopathol Pharmacol ; 32: 2058738418757925, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29442526

RESUMEN

Actinic keratosis (AK) is a clinical condition characterized by keratinocytic dysplastic lesions of the epidermis, affecting individuals chronically exposed to sunlight. Topical therapies allow the treatment of a whole area of affected skin and currently include diclofenac sodium gel, 5-fluorouracil cream, 5-fluorouracil and acetylsalicylic acid solution, imiquimod cream, and ingenol mebutate gel. Due to the comparable efficacy of 3% diclofenac, ingenol mebutate, and 3.75% imiquimod in treating AK multiple lesions, a pharmacoeconomic evaluation of cost-effectiveness of the three treatments was needed. A cost-efficacy analysis comparing 3% diclofenac sodium with ingenol mebutate and 3.75% imiquimod was performed. In this analysis, efficacy data were combined with quality-of-life measurement derived from previous studies as well as the costs associated with the management of these lesions in Italy. Patients' demographics and clinical characteristics were assumed to reflect those from the clinical studies considered.


Asunto(s)
Aminoquinolinas/economía , Análisis Costo-Beneficio/métodos , Diclofenaco/economía , Diterpenos/economía , Queratosis Actínica/tratamiento farmacológico , Queratosis Actínica/economía , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/economía , Aminoquinolinas/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/economía , Ensayos Clínicos Fase III como Asunto/economía , Árboles de Decisión , Diclofenaco/administración & dosificación , Diterpenos/administración & dosificación , Composición de Medicamentos , Humanos , Imiquimod , Estudios Multicéntricos como Asunto/economía , Ensayos Clínicos Controlados Aleatorios como Asunto/economía , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA